Literature DB >> 17063080

The mismatch repair protein status of colorectal small cell neuroendocrine carcinomas.

Edward B Stelow1, Christopher A Moskaluk, Stacey E Mills.   

Abstract

Small cell neuroendocrine carcinoma (SCNC) of the colorectum is a rare and highly aggressive malignancy. It can be associated with conventional-type adenocarcinoma, and an overlying adenoma can often be identified. A disproportionate number has been noted to arise in the right colon. Although some phenotypes (eg, mucinous adenocarcinoma) have been shown to be associated with deficient mismatch repair (MMR) and thus microsatellite instability (MSI), the MMR protein status of colorectal SCNCs has not been investigated. This study investigated the status of 3 MMR proteins, hMLH1, hMSH2, and hMSH6, in SCNCs of the colorectum. Fifteen SCNCs were identified on the basis of previous descriptions and the World Health Organization histologic criteria for the diagnosis of pulmonary small cell carcinoma and immunohistochemical evidence of epithelial and neuroendocrine differentiation. Patient age and sex and tumor size and location were recorded. Immunohistochemistry was performed with antibodies to pancytokeratin (cocktail), CD56, neuron specific enolase, synaptophysin, chromogranin, hMLH1, hMSH2, and hMSH6. Patients' ages ranged from 44 to 87 years (mean age = 73 y) and there were 9 men and 6 women. Tumors were located in the right colon (6), sigmoid colon (4), and rectum (3) (the locations of 2 cases were not recorded) and ranged in size from 0.4 to 15 cm in greatest dimension (mean = 6.6 cm). All tumors showed immunoreactivity with antibodies to pancytokeratin and with antibodies to at least 1 neuroendocrine antigen. MMR proteins were intact by immunohistochemistry in all but a single case that had neither an identifiable precursor lesion nor positive internal control (hMLH1 loss). Colorectal SCNCs are rare and are often right-sided. They are aggressive and tend to occur in older individuals. Most colorectal SCNCs have intact MMR proteins, suggesting that they develop secondary to chromosomal instability rather than MSI. Our single case showing potential MMR protein loss suggests that this phenotype may be independent of the developmental pathway (ie, chromosomal instability vs. MSI). This may explain the rare cases of SCNC that have been identified in patients with hereditary nonpolyposis colon cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063080     DOI: 10.1097/01.pas.0000213272.15221.38

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

Review 1.  Pathologic research update of colorectal neuroendocrine tumors.

Authors:  Shu-Juan Ni; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

2.  Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.

Authors:  Trilokesh D Kidambi; Christina Pedley; Amie Blanco; Emily K Bergsland; Jonathan P Terdiman
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

3.  Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation.

Authors:  Toshihide Komatsubara; Koji Koinuma; Yasuyuki Miyakura; Hisanaga Horie; Mitsuaki Morimoto; Homare Ito; Alan K Lefor; Naohiro Sata; Noriyoshi Fukushima
Journal:  Clin J Gastroenterol       Date:  2015-12-23

4.  A case of strongly suspected Lynch syndrome with colorectal neuroendocrine carcinoma.

Authors:  Naoya Kobayashi; Hiroshi Yoshida; Shinya Kawaguchi; Satoru Shiraso; Noriko Nemoto; Nanako Fujikawa; Yoichi Haji; Emiko Kono; Shoji Kokubo; Kazuhiko Tsukuda; Shigeyuki Asano; Fumiaki Shinya
Journal:  Surg Case Rep       Date:  2022-06-17

5.  Neuroendocrine Carcinoma of the Endometrium: A Clinicopathologic Study of 25 Cases.

Authors:  Cady E Pocrnich; Preetha Ramalingam; Elizabeth D Euscher; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 6.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Authors:  Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge
Journal:  Diagnostics (Basel)       Date:  2015-04-08

7.  Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas?

Authors:  Tu Vinh Luong; Zaibun Nisa; Jennifer Watkins; Aimee R Hayes
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-07-29

8.  Histopathology of gastrointestinal neuroendocrine neoplasms.

Authors:  Kenichi Hirabayashi; Giuseppe Zamboni; Takayuki Nishi; Akira Tanaka; Hiroshi Kajiwara; Naoya Nakamura
Journal:  Front Oncol       Date:  2013-01-22       Impact factor: 6.244

9.  Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.

Authors:  Christoph Fraune; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Tania Amin; Fabrice Viol; Wilfrid Fehrle; David Dum; Doris Höflmayer; Eike Burandt; Till Sebastian Clauditz; Daniel Perez; Jakob Izbicki; Waldemar Wilczak; Guido Sauter; Stefan Steurer; Jörg Schrader
Journal:  Endocr Pathol       Date:  2020-06       Impact factor: 3.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.